Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab

Launched by ABBVIE · Dec 9, 2015

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject has a diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis).
• • Male or female subject ≥ 18 years of age (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label.
• • Patients with moderate to severe RA defined as Disease Activity Score in 28 Joints (DAS28) (ESR) or DAS28 (CRP) \> 3.2
• • Biologically treatment naïve and initiated adalimumab at baseline visit
• • Availability of clinical data of the previous 12 weeks prior to baseline
• • Ability to self-complete patient questionnaires
• • Subject must be able and willing to provide written informed consent and comply with the requirements of this study protocol.
• Exclusion Criteria:
• • Patients who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks.
• • Participation in any RA-related clinical trial at the time of enrolment, at baseline or at any point during the past 24 weeks prior to baseline
• • Patients who in the clinician's view, may not be able to accurately report their QoL or prior resource utilization
• • Patients who in the clinician's view, may not be able to adhere to adalimumab therapy over 24 weeks.